Prophylactic Ivermectin in COVID-19 Contacts

• Status: Completed
• Trial end date: 2020-07-27
• Target enrollment: 0
• Participant gender: All

Summary

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms & diagnosis of COVID -19

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zagazig University
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

family contact of confirmed COVID-19 case

Exclusion Criteria:

• refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin